Pfizer Inc reported
today that a new study of men with erectile dysfunction (ED) taking Viagra
(sildenafil citrate) for 2-3 years found that 96 percent of them remain
satisfied with the effect of treatment.
The longest post-approval satisfaction study of Viagra to date, reviewed data from three separate studies of patients from the USA, Europe, Canada, and Australia. The 2618 men in the study had ED of at least 6 month's duration and the average time since first diagnosis was 4.9 years. Their average age was 56 years (range 20-91 years).
"These were very encouraging results," said lead investigator, Harin Padma-Nathan, M.D., Associate Professor, USC Department of Urology, who presented the results this week at the 9th World Meeting on Impotence Research in Perth, Australia. "It is reassuring to know that Viagra can be a long-term solution for erectile dysfunction that patients will feel good about."
Among study participants, ED was most commonly caused by vascular or other organic disorders (48 percent), followed by a mixed organic and psychogenic causes (29 percent) and exclusively psychogenic causes (21 percent). 73 percent of patients were receiving a 100 mg dose of Viagra at the 12-month endpoint.
Study results showed that Viagra was well tolerated with a low incidence of discontinuations (2.1 percent). A few patients (3.1 percent) had their dose reduced or temporarily discontinued treatment due to adverse events. The most common adverse events were headache, flushing and indigestion.
These data are results of three 12-month open-label, non-comparative, flexible-dose Viagra (25-100 mg) studies. Study participants had previously completed and were compliant with an open-extension study of Viagra. Evaluation took place at the end of each 12-month study or at discontinuation.
Viagra has been approved
by regulatory authorities in over 100 countries around the world. It is
a prescription medication available only from doctors and should always
be used in accordance with its approved labeling. Viagra is contraindicated
in patients who use nitrates.